| Literature DB >> 36082216 |
Shuning Chen1, Hao Su1, Xinhong Liu1, Qiaochu Li1, Yingchi Yao1, Jiachen Cai1, Ye Gao1, Qirui Ma1, Yajun Shi1.
Abstract
Objective: Fat loss theory under various oxygen conditions has been disputed, and relevant systematic review studies are limited. This study is a systematic review and meta-analysis to assess whether hypoxic exercise training (HET) leads to superior fat-reducing compared with normoxic exercise training (NET).Entities:
Keywords: body composition; glycometabolism; hypoxic exercise; lipometabolism; meta-analysis; normoxic exercise; obesity
Year: 2022 PMID: 36082216 PMCID: PMC9447682 DOI: 10.3389/fphys.2022.940749
Source DB: PubMed Journal: Front Physiol ISSN: 1664-042X Impact factor: 4.755
Main characteristics of studies included in the meta-analysis.
| Study | Participants characteristics | Intervention | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Participants (M/F) | Age | BMI/BFR | Duration | Frequency | Type/modality | Exercise intensity | Hypoxic condition | Type of hypoxia | Outcome | |||
| HET | NET | HET | NET | |||||||||
| Camacho-Cardenosa, A,2018 | 15 (0/15) | 18 (0/18) | 37.40 ± 10.25 | 40.05 ± 8.66 | >25 kg/m2 | 12 weeks | 3 days/wk | Repeated-sprint training; cycling | Exercise: (130% Wmax; 30 s); Active recovery: (55–65% Wmax; 3 min) | FiO2 = 17.2% | Normobaric | WC, HC, WHR, BFR,TG, TC, Glucose |
| Camacho-Cardenosa, A,2018a | 13 (0/13) | 15 (0/15) | 44.43 ± 7.18 | 43.14 ± 7.67 | >25 kg/m2 | 12 weeks | 3 days/wk | IT, cycling | Exercise: (90% Wmax; 3 min); Active recovery: (55–65% Wmax; 3 min) | FiO2 = 17.2% | Normobaric | WC, HC, WHR, BFR,TG, TC, Glucose |
| Chacaroun, S,2020 | 12 (11/1) | 11 (8/3) | 52 ± 12 | 56 ± 11 | > 27 kg/m2 | 8 weeks | 3 days/wk | Endurance; cycling | 75% (±2%) HRmax; 45 min | FiO2 = 13% | Normobaric | FBM, BMI, WC, HC, Glucose, Insulin |
| Fernandez, M,2018 | 12 (2/10) | 11 (2/9) | 34.8 ± 4.7 | 32.2 ± 8.4 | >30 kg/m2 | 3 weeks | — | Endurance; walking | six different speeds; 60 min | FiO2 = 14.5% | Normobaric | BM, BMI,FBM,TC,TG,HDL-C,LDL-C, Glucose, Insulin |
| Gatterer, H,2015 | 16 (4/12) | 16 (6/10) | 50.3 ± 10.3 | 52.4 ± 7.9 | >30 kg/m2 | 8 m | 2 days/wk | Endurance; cycling | 65–70% HRmax; 90 min | Exercise: FiO2 = 14.0 ± 0.2%; Rest: FiO2 = 12.2 ± 0.3% | Normobaric | BM, BMI, WC, HC, WHR, BFR,TG, TC, HDL-C, Glucose |
| Gonzalez-Muniesa, P,2015 | 14 (14/0) | 12 (12/0) | 25–50 | 25–50 | >30 kg/m2 | 13 weeks | 2 days/wk | Endurance/Strength; cycling | No mention; 1 h | FiO2 = 16.7%–13.7% | Normobaric | BM, BMI, WC, HC, WHR, BFR,TG, TC, LDL-C, HDL-C |
| Hobbins, L,2021 | 8 (4/4) | 8 (5/3) | 32.1 ± 10.2 | 41.1 ± 13.0 | 27–35 kg/m2 | 2 weeks | 4 days/wk | IT; walking | self-paced,60min | FiO2 = 13.0% | Normobaric | BM, BMI |
| Jung, K,2020 | 12 (0/12) | 10 (0/10) | 47.2 ± 6.4 | 43.8 ± 8.6 | >25 kg/m2 | 12 weeks | 4∼5 days/wk | Endurance; Pilates | 75% HRmax; 50 min | FiO2 = 14.5% | Normobaric | BM, BMI, BFR, TG, TC, LDL-C,HDL-C, Glucose, Insulin |
| Klug, L,2018 | 12 (12/0) | 11 (11/0) | 57.6 ± 2.2 | 55.0 ± 2.1 | >305 kg/m2 | 6 weeks | 3 days/wk | Endurance; running | 50–60% HRmax; 60 min | FiO2 = 15% | Normobaric | BM, BMI, WC,HC,WHR,BFR,TG,HDL-C,LDL-C, Glucose, Insulin |
| Kong, Z,2014 | 10 (5/5) | 8 (5/3) | 19.8 ± 2.2 | 22.3 ± 1.7 | >27.5 kg/m2 | 4 weeks | 3∼4 days/wk | Endurance/Strength; cycling, running, stepping | 60–70% HRmax; 1 h.40–50% maximal strength, three sets of 15–20 RM with 2–3 min of rest between sets | FiO2 = 16.4%–14.5% | Normobaric | BM, FBM, BMI, WHR |
| Kong, Z,2017 | 11 | 13 | 18–30 | 18–30 | 25.8 ± 2.3 kg/m2 | 5 weeks | 4 days/wk | IT; cycling | 8-s maximum; 60 repetitions | FiO2 = 15% | Normobaric | BM, BMI, FBM,BFR,TC,TG,HDL-C,LDL-C |
| Morishima, T,2014 | 9 (9/0) | 11 (11/0) | 30 ± 2 | 32 ± 3 | >25 kg/m2 | 4 weeks | 3 days/wk | Endurance; cycling | 55%VO2max; 60 min | FiO2 = 15% | Normobaric | BM, FBM, BMI, BFR, TG, TC, LDL-C,HDL-C, Glucose, Insulin |
| Nishiwaki, M,2016 | 7 (0/7) | 7 (0/7) | 56 ± 1 | 56 ± 1 | >24 kg/m2 | 8 weeks | 4 days/wk | Endurance; aquatics | 50% VO2max; 0.5 h | Simulation of 2000 m altitude (6001–6038 mmHg) | Normobaric | BM, BMI,BFR,Glucose |
| Park, H,2019 | 12 (12/0) | 12 (12/0) | 66.50 ± 0.90 | 66.50 ± 0.67 | >25 kg/m2 | 12 weeks | 3 days/wk | Endurance/Strength; cycling, running | 60–70% HRmax; 90 min–100 min | FiO2 = 14.5% | Normobaric | BM, BFR, TG, TC, LDL-C,HDL-C |
| Wang, N,2012 | 11 (6/5) | 7 (4/3) | 19.5 ± 1.64 | 22.4 ± 2.07 | H:34.62 ± 5.05 kg/m2 N:35.19 ± 5.07 kg/m2 | 4 weeks | 6 days/wk | Endurance/Strength; cycling, running | M:100W, F:75 W; 4 h | FiO2 = 15.4%–14.8% | Normobaric | BM, FBM,BFR,WC,BMI,TC,TG,HDL-C,LDL-C |
| Wiesner, S,2010 | 24 (10/14) | 21 (8/13) | 42.2 ± 1.2 | 42.1 ± 1.7 | H:33.1 ± 0.3 kg/m2 N:32.5 ± 0.8 kg/m2 | 4 weeks | 3 days/wk | Endurance, running | 65% VO2max,60 min | FiO2 = 15% | Normobaric | LDL-C, BFR, WC, Insulin |
| Yang, X,2014 | 10 (10/0) | 8 (8/0) | 22.50 ± 1.27 | 22.13 ± 2.17 | >25 kg/m2 | 4 weeks | 5 days/wk | Endurance; cycling, running | HR:140–150 beats/min; 1 h | FiO2 = 15.4% | Normobaric | BM, FBM, BMI, WHR, BFR, TG, TC, LDL-C,HDL-C |
| Zhang, N,2019 | 20 (20/0) | 20 (20/0) | 22.34 ± 2.15 | 21.87 ± 2.31 | >25 kg/m2 | 1 m | 5 days/wk | Endurance; cycling | 65% V02max; 60 min | FiO2 = 15% | Normobaric | BM, FBM, BMI, BFR, TG, TC, LDL-C, HDL-C |
| Zhao, S,2016 | 9 | 9 | 18.08 ± 1.79 | 18.24 ± 2.23 | >30 kg/m2 | 8 weeks | 5 days/wk | Endurance; cycling | 65–75%V02max | FiO2 = 14.7% | Normobaric | BM, BFR |
| Zheng, B,2020 | 10 (0/10) | 10 (0/10) | 19.60 ± 1.26 | 19.38 ± 0.74 | >28% | 6 weeks | 3 days/wk | IT; cycling | Exercise: (64–76% HRmax; 10 min); Intervals: 3 min | FiO2 = 14.0 ± 0.2% | Normobaric | BM, FBM, BMI, BFR |
Data are presented as mean or range. An article presented separate study groups distinguished by the presence or absence of a.
M, male; F, female; wk, weeks; d, day; FiO2, the fraction of inspired oxygen; IT, interval training; HR, heart rate; RM, repetition maximum; VO2max, maximal oxygen consumption; BM, body mass; BMI, body mass index; BFR, body fat rate; FBM, fat body mass; WC, waist circumference; HC, hip circumference; WHR, waist-to-hip ratio; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
FIGURE 1Flow diagram of the process of article selection.
FIGURE 2The risk assessment of bias.
FIGURE 3Funnel plot of body composition outcomes.
FIGURE 4Funnel plot of glycometabolism and lipometabolism outcomes.
FIGURE 5Forest Plot of the Meta-analysis on body composition.
FIGURE 6Forest Plot of the Meta-analysis on glycometabolism and lipometabolism.
Subgroup analyses of the effects of exercise training performed in hypoxia versus normoxia on reducing the fat.
| Subgroup | Frequency (d/wk) | Duration (wk) | FiO2 (%) | age (yr) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | SMD [95%CI] |
|
|
| n | SMD [95%CI] |
|
|
| n | SMD [95%CI] |
|
|
| n | SMD [95%CI] |
|
|
| |||||
| BM | <4 | 6 | 0.03 [−0.31, 0.36] | 0.88 | 0% | 0.99 | <8 | 9 | −0.03 [−0.32, 0.26] | 0.84 | 0% | 1 | <15 | 6 | −0.06 [−0.40, 0.29] | 0.74 | 0% | 0.77 | <45 | 10 | −0.14 [−0.41, 0.13] | 0.33 | 0% | 0.96 |
| ≥4 | 7 | −0.19 [−0.56, 0.18] | 0.31 | 0% | 0.84 | ≥8 | 5 | −0.13 [−0.53, 0.27] | 0.52 | 0% | 0.59 | ≥15 | 5 | 0.02 [−0.46, 0.50] | 0.94 | 0% | 0.99 | ≥45 | 3 | −0.14 [−0.58, 0.30] | 0.54 | 0% | 0.06 | |
| BMI | <4 | 7 | 0.03 [−0.28, 0.34] | 0.83 | 0% | 0.94 | <8 | 9 | −0.09 [−0.40, 0.23] | 0.58 | 0% | 0.71 | <15 | 5 | 0.13 [−0.21, 0.47] | 0.44 | 0% | 0.92 | <45 | 9 | −0.10 [−0.38, 0.18] | 0.48 | 0% | 0.71 |
| ≥4 | 6 | −0.09 [−0.49, 0.32] | 0.67 | 0% | 0.44 | ≥8 | 4 | 0.08 [−0.27, 0.44] | 0.65 | 0% | 0.96 | ≥15 | 5 | −0.12 [−0.55, 0.31] | 0.58 | 0% | 0.52 | ≥45 | 3 | 0.07 [−0.38, 0.51] | 0.77 | 0% | 0.86 | |
| FBM | <4 | 4 | −0.10 [−0.44, 0.23] | 0.55 | 0% | 0.87 | <8 | 3 | −0.10 [−0.44, 0.23] | 0.55 | 0% | 0.87 | <15 | 2 | 0.13 [−0.35, 0.62] | 0.60 | 0% | 0.84 | <45 | 8 | - | - | - | - |
| ≥4 | 5 | −0.31 [−0.93, 0.31] | 0.33 | 0% | 0.44 | ≥8 | 5 | −0.01 [−0.40, 0.38] | 0.97 | 0% | 0.87 | ≥15 | 5 | −0.22 [−0.73, 0.29] | 0.39 | 0% | 0.67 | ≥45 | 1 | - | - | - | - | |
| BFR | <4 | 5 | 0.29 [−0.12, 0.70] | 0.16 | 41% | 0.13 | <8 | 4 | 0.22 [−0.26, 0.70] | 0.37 | 51% | 0.07 | <15 | 4 | 0.02 [−0.39, 0.43] | 0.91 | 0% | 0.78 | <45 | 6 | 0.19 [−0.32, 0.69] | 0.46 | 54% | 0.05 |
| ≥4 | 3 | −0.22[−0.74, 0.30] | 0.41 | 0% | 0.88 | ≥8 | 4 | −0.03 [−0.42, 0.37] | 0.90 | 0% | 0.92 | ≥15 | 3 | 0.38 [−0.00, 0.76] | 0.05 | 63% | 0.04 | ≥45 | 5 | −0.46 [−1.29, 0.36] | 0.27 | 75% | 0.007 | |
| TC | <4 | 6 | 0.14 [−0.18, 0.46] | 0.39 | 0% | 0.51 | <8 | 3 | 0.05 [-0.38, 0.48] | 0.82 | 0% | 0.64 | <15 | 3 | 0.00 [−0.40, 0.41] | 0.98 | 0% | 0.41 | <45 | 8 | −0.01 [−0.28, 0.27] | 0.97 | 0% | 0.40 |
| ≥4 | 5 | −0.14 [−0.55, 0.27] | 0.43 | 0% | 0.50 | ≥8 | 7 | 0.01 [−0.28, 0.30] | 0.95 | 8% | 0.37 | ≥15 | 5 | 0.18 [−0.20, 0.57] | 0.36 | 0% | 0.69 | ≥45 | 3 | 0.15 [−0.34, 0.65] | 0.54 | 0% | 0.49 | |
| TG | <4 | 5 | −0.03 [−0.33, 0.26] | 0.84 | 0% | 0.83 | <8 | 3 | 0.07 [−0.40, 0.54] | 0.76 | 41% | 0.13 | <15 | 4 | 0.19 [−0.22, 0.60] | 0.36 | 0% | 0.68 | <45 | 8 | −0.13 [−0.50, 0.25] | 0.51 | 42% | 0.10 |
| ≥4 | 5 | −0.08 [−0.65, 0.49] | 0.78 | 46% | 0.11 | ≥8 | 7 | −0.08 [−0.38, 0.22] | 0.62 | 0% | 0.85 | ≥15 | 5 | −0.33 [−0.71, 0.05] | 0.09 | 0% | 0.85 | ≥45 | 4 | 0.06 [−0.36, 0.49] | 0.76 | 0% | 0.70 | |
| HDL | <4 | 3 | 0.04 [−0.33, 0.41] | 0.83 | 48% | 0.11 | <8 | 3 | −0.04 [−0.43, 0.36] | 0.86 | 0% | 0.66 | <15 | 4 | 0.37 [−0.30, 1.03] | 0.28 | 49% | 0.14 | <45 | 6 | −0.32 [−0.69, 0.05] | 0.09 | 59% | 0.05 |
| ≥4 | 5 | 0.01 [−0.40, 0.41] | 0.98 | 0% | 0.70 | ≥8 | 5 | 0.08 [−0.30, 0.46] | 0.73 | 45% | 0.12 | ≥15 | 3 | 0.03 [−0.45, 0.52] | 0.89 | 0% | 0.50 | ≥45 | 4 | 0.19 [−0.24, 0.62] | 0.39 | 41% | 0.13 | |
| LDL | <4 | 3 | 0.18 [−0.23, 0.60] | 0.39 | 30% | 0.22 | <8 | 4 | 0.28 [−0.12, 0.68] | 0.18 | 30% | 0.21 | <15 | 5 | −0.07 [−0.54, 0.41] | 0.78 | 0% | 0.87 | <45 | 7 | −0.08 [−0.52, 0.37] | 0.73 | 48% | 0.09 |
| ≥4 | 5 | 0.34 [−0.13, 0.82] | 0.15 | 0% | 0.86 | ≥8 | 4 | 0.06 [-0.37, 0.48] | 0.26 | 0% | 0.94 | ≥15 | 4 | 0.54 [−0.61, 1.68] | 0.36 | 78% | 0.03 | ≥45 | 4 | 0.50 [−0.22, 1.22] | 0.17 | 46% | 0.16 | |
| Glucose | <4 | 6 | 0.16 [−0.16, 0.48] | 0.32 | 0% | 0.62 | <8 | 3 | −0.41 [−0.91, 0.08] | 0.10 | 25% | 0.26 | <15 | 4 | −0.05 [−0.46, 0.36] | 0.81 | 59% | 0.06 | <45 | 4 | 0.06 [−0.34, 0.45] | 0.78 | 68% | 0.02 |
| ≥4 | 2 | 0.31 [−0.36, 0.98] | 0.37 | 40% | 0.20 | ≥8 | 6 | 0.29 [−0.04, 0.61] | 0.09 | 0% | 0.56 | ≥15 | 5 | 0.17 [−0.20, 0.54] | 0.37 | 0% | 0.43 | ≥45 | 4 | −0.05 [−0.47, 0.37] | 0.81 | 0% | 0.97 | |
| Insulin | <4 | 4 | - | - | - | - | <8 | 4 | 0.18 [−0.20, 0.55] | 0.36 | 0% | 0.64 | <15 | 3 | 0.01 [−0.47, 0.49] | 0.96 | 15% | 0.31 | <45 | 3 | 0.10 [−0.32, 0.52] | 0.63 | 0% | 0.57 |
| ≥4 | 1 | - | - | - | - | ≥8 | 2 | −0.22 [−0.81, 0.37] | 0.47 | 0% | 0.45 | ≥15 | 3 | 0.10 [−0.32, 0.52] | 0.65 | 0% | 0.60 | ≥45 | 2 | 0.23 [−0.36, 0.81] | 0.45 | 0% | 0.44 | |
n, number of studies. -, absence of studies for a given subgroup. BM, body mass; BMI, body mass index; BFR, body fat rate; FBM, fat body mass; WC, waist circumference; HC, hip circumference; WHR, waist-to-hip ratio; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.